EarliTec Diagnostics Raises $21.5M in Series B Funding

EarliTec Diagnostics, a Decatur, GA-based medical device company, raised $21.5M in Series B funding.

The round was led by Nexus NeuroTech Ventures and Venture Investors Health Fund.

The company intends to use the funds to expand commercialization efforts and advance clinical research for the EarliPoint™ Evaluation, which aids clinicians in the diagnosis and assessment of autism in children aged 16-to-30 months.

Led by Ami Klin, Ph.D., Chief Clinical Officer and Founder, and Tom Ressemann, Chief Executive Officer, EarliTec Diagnostics is a medical device company making earlier identification and treatment for autism and related early childhood vulnerabilities accessible to children everywhere. Developed by researchers at Children’s Healthcare of Atlanta, Emory University School of Medicine and Yale University, the company is pioneering the development of biomarkers that help parents and providers understand how a child is looking and learning from the world around them. The technology was developed through extensive research funded by philanthropist Bernie Marcus. Its initial product, the EarliPoint Evaluation, is the first objective measurement tool that clinicians can use to aid in the diagnosis and assessment of autism in children as young as 16 months. As of today, 12 EarliPoint devices are in 8 centers across 6 states in the U.S.